Cingulate Inc. Reports First Quarter 2023 Financial Results and Provides Clinical and…
<!-- Name:DistributionId Value:8836312 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Browsing Tag
CTx-1301
Cingulate Announces Positive Top-Line Results from Fed/Fast Study of Lead Asset…
<!-- Name:DistributionId Value:8755907 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Cingulate Completes Fed/Fast Study Assessing Food Effect with CTx-1301, Lead…
KANSAS CITY, Kan., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery…